Physician profile
Michael Schulman
NPI 1700971017
$58,206.16
in general payments reported to CMS, 2019-2025
54 companies · $9,395 in 2025
The $9,395 reported for 2025 was more than what 93% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,383 · 2020: $7,427 · 2021: $8,015 · 2022: $11K · 2023: $4,574 · 2024: $10K · 2025: $9,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $9,688 · Consulting Fee: $1,200 · Travel and Lodging: $204 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,955.00 |
| Food and Beverage | $9,688.32 |
| Consulting Fee | $1,200.00 |
| Travel and Lodging | $204.46 |
| Education | $147.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $22,914.11 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Phathom Pharmaceuticals, INC. | $8,870.90 | 2024-2025 | Voquezna |
| Palette Life Sciences, INC. | $4,216.76 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $3,273.81 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,927.52 | 2019-2025 | Xifaxan, Relistor, Trulance |
| Allergan, INC. | $2,652.25 | 2019 | |
| Janssen Biotech, INC. | $2,121.38 | 2019-2025 | Stelara, Tremfya, Simponi |
| Alfasigma USA, INC. | $2,043.68 | 2020 | |
| Gilead Sciences, INC. | $825.25 | 2019-2025 | Livdelzi, Epclusa |
| Madrigal Pharmaceuticals | $790.74 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $619.01 | 2019-2025 | |
| Ardelyx, INC. | $565.25 | 2022-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $564.22 | 2022-2025 | Dupixent |
| Qol Medical, LLC | $426.74 | 2019-2025 | Sucraid, Sucraid |
| Redhill Biopharma INC. | $417.43 | 2021-2023 | Talicia, Movantik, Aemcolo |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $416.34 | 2021-2025 | |
| Celgene Corporation | $364.25 | 2019-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $322.78 | 2019-2025 | |
| Evoke Pharma, INC. | $311.56 | 2021-2025 | Gimoti |
| E.R. Squibb & Sons, L.L.C. | $276.01 | 2021-2023 | Zeposia |
| Shionogi INC | $273.16 | 2019 | |
| Boston Scientific Corporation | $240.94 | 2019-2025 | Axonics |
| Nestle Healthcare Nutrition INC. | $225.57 | 2020-2023 | |
| Ironwood Pharmaceuticals, INC | $214.60 | 2019-2025 | Linzess |
| Aimmune Therapeutics, INC. | $204.31 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $191.40 | 2024-2025 | Zymfentra, Vegzelma |
| Lilly USA, LLC | $191.07 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $183.32 | 2019-2021 | |
| Vivus LLC | $158.07 | 2019-2023 | Pancreaze |
| Intra-Sana Laboratories | $144.75 | 2022 | |
| Concordia Pharmaceuticals INC. | $135.72 | 2019 | |
| Janssen Scientific Affairs, LLC | $131.53 | 2019-2021 | |
| Ferring Pharmaceuticals INC. | $122.12 | 2024 | Rebyota |
| Amgen INC. | $81.41 | 2020-2023 | Avsola, Amjevita |
| Braintree Laboratories, INC. | $78.25 | 2020-2024 | Suflave, Sutab |
| Medtronic, INC. | $77.52 | 2022 | |
| Merck Sharp & Dohme LLC | $75.57 | 2021-2023 | Zerbaxa, Dificid, Recarbrio |
| Napo Pharmaceuticals INC | $75.44 | 2019 | |
| Romark Laboratories, Lc | $68.93 | 2019-2020 | |
| Fresenius Kabi USA, LLC | $65.70 | 2023-2025 | Idacio, Adalimumab-Aacf |
| Pharmacosmos Therapeutics INC. | $57.82 | 2021-2024 | Monoferric |
| Axonics, INC. | $57.36 | 2024 | Axonics |
| Ucb, INC. | $47.16 | 2019-2020 | |
| Mauna Kea Technologies, INC. | $36.15 | 2019 | |
| Fujifilm Healthcare Americas Corporation | $25.66 | 2023 | Fujifilm |
| Tempus Ai, INC | $24.29 | 2025 | Xt Cdx |
| Novo Nordisk INC | $22.08 | 2025 | Wegovy |
| Amag Pharmaceuticals, INC. | $18.82 | 2019 | |
| Shield Therapeutics INC | $14.98 | 2025 | |
| Lucid Diagnostics INC. | $14.36 | 2023 | |
| Endo Pharmaceuticals INC. | $14.22 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $13.89 | 2025 | Iqirvo |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schulman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.